• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

从非酒精性脂肪性肝病到肝癌:微生物群与炎症作为关键因素

From Non-Alcoholic Fatty Liver Disease to Liver Cancer: Microbiota and Inflammation as Key Players.

作者信息

Rodríguez-Lara Avilene, Rueda-Robles Ascensión, Sáez-Lara María José, Plaza-Diaz Julio, Álvarez-Mercado Ana I

机构信息

Center of Biomedical Research, Institute of Nutrition and Food Technology "José Mataix", University of Granada, Avda. del Conocimiento s/n., Armilla, 18016 Granada, Spain.

Department of Nutrition and Food Science, Faculty of Pharmacy, University of Granada,18071 Granada, Spain.

出版信息

Pathogens. 2023 Jul 15;12(7):940. doi: 10.3390/pathogens12070940.

DOI:10.3390/pathogens12070940
PMID:37513787
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10385788/
Abstract

It is estimated that 25% of the world's population has non-alcoholic fatty liver disease. This disease can advance to a more severe form, non-alcoholic steatohepatitis (NASH), a disease with a greater probability of progression to cirrhosis and hepatocellular carcinoma (HCC). NASH could be characterized as a necro-inflammatory complication of chronic hepatic steatosis. The combination of factors that lead to NASH and its progression to HCC in the setting of inflammation is not clearly understood. The portal vein is the main route of communication between the intestine and the liver. This allows the transfer of products derived from the intestine to the liver and the hepatic response pathway of bile and antibody secretion to the intestine. The intestinal microbiota performs a fundamental role in the regulation of immune function, but it can undergo changes that alter its functionality. These changes can also contribute to cancer by disrupting the immune system and causing chronic inflammation and immune dysfunction, both of which are implicated in cancer development. In this article, we address the link between inflammation, microbiota and HCC. We also review the different in vitro models, as well as recent clinical trials addressing liver cancer and microbiota.

摘要

据估计,全球25%的人口患有非酒精性脂肪性肝病。这种疾病可能会发展为更严重的形式,即非酒精性脂肪性肝炎(NASH),这种疾病更有可能发展为肝硬化和肝细胞癌(HCC)。NASH可被视为慢性肝脂肪变性的坏死性炎症并发症。在炎症背景下,导致NASH及其发展为HCC的多种因素组合尚不清楚。门静脉是肠道与肝脏之间的主要沟通途径。这使得源自肠道的产物能够转移至肝脏,同时肝脏胆汁分泌及抗体分泌的反应途径也能作用于肠道。肠道微生物群在免疫功能调节中发挥着重要作用,但它可能会发生改变,进而影响其功能。这些变化也可能通过破坏免疫系统、引发慢性炎症和免疫功能紊乱而导致癌症,而这两者都与癌症发展有关。在本文中,我们阐述了炎症、微生物群与HCC之间的联系。我们还回顾了不同的体外模型,以及近期针对肝癌与微生物群的临床试验。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c6a/10385788/211e6cbc09e8/pathogens-12-00940-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c6a/10385788/51b56ff7e5cc/pathogens-12-00940-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c6a/10385788/211e6cbc09e8/pathogens-12-00940-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c6a/10385788/51b56ff7e5cc/pathogens-12-00940-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c6a/10385788/211e6cbc09e8/pathogens-12-00940-g002.jpg

相似文献

1
From Non-Alcoholic Fatty Liver Disease to Liver Cancer: Microbiota and Inflammation as Key Players.从非酒精性脂肪性肝病到肝癌:微生物群与炎症作为关键因素
Pathogens. 2023 Jul 15;12(7):940. doi: 10.3390/pathogens12070940.
2
Gut microbiota, fatty liver disease, and hepatocellular carcinoma.肠道微生物群、脂肪性肝病和肝细胞癌
Liver Res. 2018 Mar;2(1):43-51. doi: 10.1016/j.livres.2017.11.005. Epub 2018 Feb 21.
3
Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives.了解肠道微生物组和微生物代谢物在非酒精性脂肪性肝病中的作用:当前的证据和观点。
Biomolecules. 2021 Dec 31;12(1):56. doi: 10.3390/biom12010056.
4
Role of immune responses in the development of NAFLD-associated liver cancer and prospects for therapeutic modulation.免疫反应在非酒精性脂肪性肝病相关肝癌的发生发展中的作用及治疗调节的前景。
J Hepatol. 2023 Aug;79(2):538-551. doi: 10.1016/j.jhep.2023.02.033. Epub 2023 Mar 7.
5
The Role of Gut-Liver Axis in Gut Microbiome Dysbiosis Associated NAFLD and NAFLD-HCC.肠-肝轴在肠道微生物群失调相关的非酒精性脂肪性肝病和非酒精性脂肪性肝病-肝癌中的作用
Biomedicines. 2022 Feb 23;10(3):524. doi: 10.3390/biomedicines10030524.
6
Blocking integrin αβ-mediated CD4 T cell recruitment to the intestine and liver protects mice from western diet-induced non-alcoholic steatohepatitis.阻断整合素 αβ 介导的 CD4 T 细胞向肠道和肝脏的募集可保护小鼠免受西式饮食诱导的非酒精性脂肪性肝炎。
J Hepatol. 2020 Nov;73(5):1013-1022. doi: 10.1016/j.jhep.2020.05.047. Epub 2020 Jun 12.
7
Gut microbiota contribution to hepatocellular carcinoma manifestation in non-alcoholic steatohepatitis.肠道微生物群对非酒精性脂肪性肝炎中肝细胞癌表现的影响
World J Hepatol. 2022 Jul 27;14(7):1277-1290. doi: 10.4254/wjh.v14.i7.1277.
8
Discovering Biomarkers for Non-Alcoholic Steatohepatitis Patients with and without Hepatocellular Carcinoma Using Fecal Metaproteomics.利用粪便代谢组学发现伴有和不伴有肝细胞癌的非酒精性脂肪性肝炎患者的生物标志物。
Int J Mol Sci. 2022 Aug 9;23(16):8841. doi: 10.3390/ijms23168841.
9
Alcohol, microbiome, life style influence alcohol and non-alcoholic organ damage.酒精、微生物群、生活方式会影响酒精性和非酒精性器官损伤。
Exp Mol Pathol. 2017 Feb;102(1):162-180. doi: 10.1016/j.yexmp.2017.01.003. Epub 2017 Jan 7.
10
Gut microbiota abnormalities, small intestinal bacterial overgrowth, and non-alcoholic fatty liver disease: An emerging paradigm.肠道微生物群异常、小肠细菌过度生长与非酒精性脂肪性肝病:一种新兴模式。
Indian J Gastroenterol. 2020 Feb;39(1):9-21. doi: 10.1007/s12664-020-01027-w.

引用本文的文献

1
Intratumoral Microbe Correlated with Expression of DNA Methylation Genes in Hepatocellular Carcinoma.肝癌中肿瘤内微生物与DNA甲基化基因表达的相关性
Dig Dis Sci. 2025 Jul 25. doi: 10.1007/s10620-025-09157-x.
2
Impact of gut microbiota on metabolic dysfunction-associated steatohepatitis and hepatocellular carcinoma: pathways, diagnostic opportunities and therapeutic advances.肠道微生物群对代谢相关脂肪性肝炎和肝细胞癌的影响:途径、诊断机会和治疗进展。
Eur J Med Res. 2024 Oct 5;29(1):485. doi: 10.1186/s40001-024-02072-3.
3
AMPK-Mediated Hypolipidemic Effects of a and Mixed Extract on High-Fat Diet-Induced Liver Triglyceride Accumulation: An In Vivo and In Vitro Study.

本文引用的文献

1
A gut bacterial signature in blood and liver tissue characterizes cirrhosis and hepatocellular carcinoma.血液和肝组织中的肠道细菌特征可用于表征肝硬化和肝细胞癌。
Hepatol Commun. 2023 Jun 14;7(7). doi: 10.1097/HC9.0000000000000182. eCollection 2023 Jul 1.
2
Intestinal B cells license metabolic T-cell activation in NASH microbiota/antigen-independently and contribute to fibrosis by IgA-FcR signalling.肠 B 细胞在 NASH 微生物群/抗原非依赖性条件下许可代谢性 T 细胞激活,并通过 IgA-FcR 信号传导促进纤维化。
J Hepatol. 2023 Aug;79(2):296-313. doi: 10.1016/j.jhep.2023.04.037. Epub 2023 May 22.
3
Liver Organoids as an In Vitro Model to Study Primary Liver Cancer.
AMPK 介导的 和 混合提取物对高脂饮食诱导的肝脏甘油三酯积累的降脂作用:体内和体外研究。
Nutrients. 2024 Sep 20;16(18):3189. doi: 10.3390/nu16183189.
4
NAFLD/MASLD and the Gut-Liver Axis: From Pathogenesis to Treatment Options.非酒精性脂肪性肝病/代谢功能障碍相关脂肪性肝病与肠-肝轴:从发病机制到治疗选择
Metabolites. 2024 Jun 28;14(7):366. doi: 10.3390/metabo14070366.
5
Liver cancer wars: plant-derived polyphenols strike back.肝癌之战:植物源多酚类物质奋起反击。
Med Oncol. 2024 Apr 16;41(5):116. doi: 10.1007/s12032-024-02353-1.
6
Prevalence of Non-Alcoholic Fatty Liver Disease in Adult Individuals with Moderate-to-Severe Atopic Dermatitis.中度至重度特应性皮炎成年个体中非酒精性脂肪性肝病的患病率
J Clin Med. 2023 Sep 19;12(18):6057. doi: 10.3390/jcm12186057.
7
The future of affordable cancer immunotherapy.平价癌症免疫疗法的未来。
Front Immunol. 2023 Sep 6;14:1248867. doi: 10.3389/fimmu.2023.1248867. eCollection 2023.
肝类器官作为研究原发性肝癌的体外模型。
Int J Mol Sci. 2023 Feb 25;24(5):4529. doi: 10.3390/ijms24054529.
4
suppressing nonalcoholic steatohepatitis associated tumorigenesis through CXCR6 natural killer T cells.通过 CXCR6 自然杀伤 T 细胞抑制非酒精性脂肪性肝炎相关肿瘤发生。
Front Immunol. 2022 Dec 1;13:1047570. doi: 10.3389/fimmu.2022.1047570. eCollection 2022.
5
Association of gut microbiome and primary liver cancer: A two-sample Mendelian randomization and case-control study.肠道微生物群与原发性肝癌的关联:一项两样本孟德尔随机化和病例对照研究。
Liver Int. 2023 Jan;43(1):221-233. doi: 10.1111/liv.15466. Epub 2022 Nov 8.
6
Liver organoids: an in vitro 3D model for liver cancer study.肝类器官:一种用于肝癌研究的体外三维模型。
Cell Biosci. 2022 Sep 9;12(1):152. doi: 10.1186/s13578-022-00890-8.
7
The effect of increasing intestinal short-chain fatty acid concentration on gut permeability and liver injury in the context of liver disease: A systematic review.增加肠道短链脂肪酸浓度对肝病时肠道通透性和肝损伤的影响:系统评价。
J Gastroenterol Hepatol. 2022 Aug;37(8):1498-1506. doi: 10.1111/jgh.15899. Epub 2022 May 31.
8
Neutrophil extracellular traps enriched with IL-1β and IL-17A participate in the hepatic inflammatory process of patients with non-alcoholic steatohepatitis.富含白细胞介素-1β和白细胞介素-17A 的中性粒细胞胞外诱捕体参与非酒精性脂肪性肝炎患者的肝脏炎症过程。
Virchows Arch. 2022 Sep;481(3):455-465. doi: 10.1007/s00428-022-03330-7. Epub 2022 May 3.
9
Microbiota in health and diseases.肠道菌群与健康和疾病。
Signal Transduct Target Ther. 2022 Apr 23;7(1):135. doi: 10.1038/s41392-022-00974-4.
10
Implication of Intestinal Barrier Dysfunction in Gut Dysbiosis and Diseases.肠道屏障功能障碍在肠道菌群失调和疾病中的影响
Biomedicines. 2022 Jan 27;10(2):289. doi: 10.3390/biomedicines10020289.